Apimeds Pharmaceuticals US, Inc
AMEX: APUS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Vinod Menon
- Employees
- 2
- Headquarters
- Hopewell, United States
- IPO year
- 2025
- Market cap
- $1.4M
- Website
- https://www.apimedsus.com
Loading APUS…
Loading profile data…Frequently asked questions about APUS
What does Apimeds Pharmaceuticals US, Inc (APUS) do?
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical...
Where does APUS trade?
Apimeds Pharmaceuticals US, Inc (APUS) trades on the New York Stock Exchange American.
What sector is APUS in?
Apimeds Pharmaceuticals US, Inc (APUS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Apimeds Pharmaceuticals US, Inc?
Vinod Menon is the chief executive officer of Apimeds Pharmaceuticals US, Inc (APUS).
Where is Apimeds Pharmaceuticals US, Inc headquartered?
Apimeds Pharmaceuticals US, Inc is headquartered in United States.
Does APUS pay a dividend?
Apimeds Pharmaceuticals US, Inc (APUS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did APUS go public?
Apimeds Pharmaceuticals US, Inc (APUS) completed its initial public offering in 2025.